There are few published reports of outcomes with micropulse TSCPC, but the limited data available are encouraging. Investigators at the National University of Singapore initially published their experience treating 40 eyes with refractory glaucoma [Tan et al. Clin Exp Ophthalmol. 2010;38(3):266-272.]
Mean IOP averaged 39.3 mm Hg at baseline and decreased to 26.6 mm Hg at 1 year. There were no cases of hypotony or phthisis.
Subsequently, they reported results from a study randomizing 48 eyes with refractory glaucoma to micropulse or continuous wave TSCPC [Aquino et al. Clin Exp Ophthalmol. 2015;43(1):40-46]. Success, defined as IOP between 6 mm Hg and 21 mm Hg with at least a 30% reduction in IOP with or without medications at 18 months, was achieved by 52% of eyes treated with micropulse CPC and by only 30% of those treated with continuous wave TSCPC.
Dr. Craven also presented data collected in a prospective observational study by Shan Lin, MD, University of California, San Francisco. The series included 57 eyes treated from June 2015 to August 2016. The majority of eyes (75%) had primary open angle glaucoma, but the entire spectrum of glaucoma diagnoses was represented in the remaining eyes, and 30% had had prior filtration surgery.
In an analysis of outcomes from follow-up at 6 or 12 months post-treatment and excluding 7 eyes that needed retreatment, mean IOP was reduced by 28%, from 23.89 mm Hg at baseline to 17 mm Hg. Mean daily medication use was reduced from 3.5 to 3.3. Success, defined as IOP lowering ≥20% with or without medications, was achieved in 68% of eyes.